文献速递糖尿病性腺与生殖内分泌

绝经激素治疗与2型糖尿病风险及预后:系统综述与荟萃分析

Menopause hormone therapy and type 2 diabetes risk and prognosis: systematic review and meta-analyses.
PubMed 文献 · Diabetologia · 2026-09-18

该系统综述与荟萃分析纳入49篇文章(33项随机对照试验和16项队列研究),涉及15个国家共1,472,277名参与者。在无2型糖尿病的女性中,绝经激素治疗(MHT)与新发2型糖尿病风险降低相关(RR 0.83,95%CI 0.75-0.92;证据确定性极低),并小幅降低空腹胰岛素和HOMA-IR。在2型糖尿病女性中,MHT与空腹血糖、HbA1c、胆固醇、LDL-C和收缩压的小幅降低相关。

要点

  • MHT或无2型糖尿病女性新发2型糖尿病风险降低相关,但证据确定性极低。
  • MHT在有无2型糖尿病女性中均显示小幅血糖代谢获益,效应量普遍不具临床显著性。
  • 研究局限性包括多为单评审员筛选、纳入研究偏倚风险高和地域代表性有限。

核心结论

  • MHT在有无2型糖尿病的女性中均与血糖代谢呈小幅有益关联,但效应量普遍过小,不具临床显著性。

研究设计与样本

  • 系统综述与荟萃分析,检索六个电子数据库从建库至2025年7月29日,纳入随机对照试验和队列研究。
  • 共纳入49篇文章(33项RCT和16项队列研究),来自15个国家,涉及1,472,277名参与者。
  • RCT研究持续时间1周至13.2年,队列研究持续时间6个月至17年;7项研究被评为低偏倚风险。

主要发现

  • 无2型糖尿病女性中,MHT使用与空腹胰岛素小幅降低相关(11项研究,N=4262,MD -5.90 pmol/l,95%CI -8.03至-3.77;高证据确定性)。
  • 无2型糖尿病女性中,MHT使用与HOMA-IR评分小幅降低相关(4项研究,N=2883,MD -0.21,95%CI -0.32至-0.09;中等证据确定性)。
  • 无2型糖尿病女性中,MHT使用与新发2型糖尿病风险降低相关(14项研究,N=1,450,134,RR 0.83,95%CI 0.75-0.92;极低证据确定性)。
  • 2型糖尿病女性中,MHT与空腹血糖小幅降低相关(16项研究,N=1379,MD -1.07 mmol/l,95%CI -1.86至-0.28;极低证据确定性)。
  • 2型糖尿病女性中,MHT与HbA1c小幅降低相关(17项研究,N=15,720,MD -5.47 mmol/mol [-0.50%],95%CI -8.32至-2.62 mmol/mol [-0.76至-0.24%];极低证据确定性)。

临床怎么用

  • MHT对血糖代谢的获益幅度普遍较小,不应以改善血糖或预防2型糖尿病为主要目的处方MHT。
  • 对于合并2型糖尿病的绝经女性,MHT可能带来小幅代谢改善,但需结合个体情况权衡利弊。

局限性

  • 研究局限性包括筛选和评估主要由单评审员完成、纳入研究偏倚风险高以及地域代表性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Menopause hormone therapy (MHT) may have effects on metabolic conditions. This study was conducted to systematically review the literature, to summarise and quantify the effect of MHT on glucose or insulin levels and on new-onset type 2 diabetes among women without type 2 diabetes and to summarise and quantify the effect of MHT on glucose, insulin, lipid and blood pressure levels among women with type 2 diabetes. METHODS: Data from six electronic databases (PubMed, Embase, Cochrane, CINAHL, PsyclNFO and MEDLINE) from inception to 29 July 2025 were searched for randomised controlled trials (RCTs) and cohort studies comparing MHT users with non-users among postmenopausal women or women undergoing the menopausal transition. Eligible studies reported the effects of MHT on glucose metabolism, lipid levels or blood pressure in women with or without type 2 diabetes. The risk of bias in RCTs and cohort studies was assessed with version 2 of the Cochrane risk-of-bias for randomised trials (RoB 2) tool and the Risk of Bias in Non-randomised Studies of Interventions (ROBINS-I) tool, respectively. Certainty of evidence (CoE) was assessed with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Random-effects models were used to estimate the pooled effects. RESULTS: In total, 49 articles (33 reporting on RCTs and 16 on cohort studies) from 15 countries were identified, involving 1,472,277 participants. The study durations ranged from 1 week to 13.2 years for RCTs and from 6 months to 17 years for cohort studies. Seven of these were assessed as having a low risk of bias. Among women without type 2 diabetes, MHT use was associated with small reductions in fasting insulin (11 studies: N=4262, mean difference [MD] -5.90 pmol/l [95% confidence interval (CI) -8.03, -3.77 pmol/l]; high CoE) and in homeostasis model assessment of insulin resistance score (four studies: N=2883, MD -0.21 [95% CI -0.32, -0.09]; moderate CoE), as well as a lower risk of new-onset type 2 diabetes (14 studies: N=1,450,134, risk ratio 0.83 [95% CI 0.75, 0.92]; very low CoE], compared with non-MHT users. Among women with type 2 diabetes, MHT was associated with small reductions in fasting plasma glucose (16 studies: N=1379, MD -1.07 mmol/l [95% CI -1.86, -0.28 mmol/l]; very low CoE), haemoglobin A1c (17 studies: N=15,720, MD -5.47 mmol/mol [-0.50%] [95% CI -8.32, -2.62 mmol/mol (-0.76, -0.24%)]; very low CoE), cholesterol (15 studies: N=907, MD -0.37 mmol/l [95% CI -0.50, -0.24 mmol/l]; low CoE), low-density lipoprotein cholesterol (16 studies: N=961, MD -0.33 mmol/l [95% CI -0.54, -0.13 mmol/l]; low CoE) and systolic blood pressure (nine studies: N=630, MD -3.43 mmHg (-0.46 kPa) [95% CI -4.88, -1.98 mmHg]; low CoE), compared with non-MHT users. CONCLUSIONS/INTERPRETATION: MHT showed small beneficial associations with glucose metabolism among women with and without type 2 diabetes, while the effect size was generally too small to be clinically significant. Future studies are needed to shed more light on the effect of MHT by initiation age. Study limitations include the predominantly single-reviewer screening and assessment, the high risk of bias of the included studies and restricted geographical representation. REGISTRATION: The study protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO; CRD420251230387). FUNDING: This work was supported by a National Health and Medical Research Council investigator grant (APP2009577).

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Liang C, Dobson AJ, Doust J, et al. Menopause hormone therapy and type 2 diabetes risk and prognosis: systematic review and meta-analyses. Diabetologia. 2026. PMID: 42758305. doi:10.1007/s00125-026-06856-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。